noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Michigan Department of Transportation

M-28 shoulder work in Chippewa County starts June 8
Boise State University

School for the Digital Future pioneers new Sport Impact Certificate
Idaho Department of Fish and Game

Four Chinook salmon seasons closed or modified starting Wednesday, June 3

Healthcare

Pappas Capital LLC

06/02/2026 | Press release | Distributed by Public on 06/02/2026 11:05

Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpa...

News | 06. 02. 2026

Aura Biosciences

BOSTON, June 01, 2026 -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced it has completed enrollment of 108 patients in the Phase 3 trial evaluating belzupacap sarotalocan (bel-sar) as a frontline treatment for patients with early choroidal melanoma. Topline data for the 15-month primary endpoint are anticipated in the second half of 2027.

Pappas Capital LLC published this content on June 02, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on June 02, 2026 at 17:05 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]

Back

View original format